King warned on Embeda VNRs

Share this article:
Video news releases (VNRs) for King's abuse-resistant pain drug Embeda drew a warning letter from FDA's Division of Drug Marketing, Advertising and Communications.

The agency said two VNRs omitted or minimized risks, including those featured in the drug's “extensive” Boxed Warning, and failed to present limitations to the approved indication. Moreover, the warning letter said King presented misleading claims – among them, those about the drug's alleged abuse-resistant properties, which have not been substantiated clinically.  

DDMAC said King agreed to pull the VNRs in August following a teleconference with regulators.

The analgesic, approved in August for the management of moderate to severe pain, contains morphine sulfate and carries a long boxed warning against potentially fatal consequences of abuse, use with alcohol and improper administration.

The agency demanded that the company furnish a list of promotional materials it has pulled, and that it disseminate corrective messaging to counteract the violative releases.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.